Press Releases

Arbor Pharmaceuticals Announces FDA Approval of First NDA

May 13, 2013

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Nymalize™ (nimodipine) oral solution. Nymalize was previously granted Orphan designation which provides seven years of market exclusivity. Nymalize is the first and only nimodipine oral solution indicated for the improvement of neurological outcome…

Read More

Eisai Inc. Divests U.S. Rights for GLIADEL® Wafer (polifeprosan 20 with carmustine implant) to Arbor Pharmaceuticals

December 17, 2012

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for Gliadel® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc.

Read More